All treatments
Treatment
Placebo to BIC/FTC/TAF clinical trials
2 indexed studies · 0 currently recruiting
- Active not recruitingPHASE3
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
This study looks at a new two-drug HIV treatment, Doravirine/Islatravir (DOR/ISL), for people living with HIV-1 who are currently doing well on another common treatment, Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF). Researchers want to see if switching to the new treatment is as effective and safe.
For: HIV-1 InfectionUnited States · Australia · Chile - Active not recruitingPHASE3
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
This study is testing a new combination medicine, DOR/ISL, for people newly diagnosed with HIV-1 who haven't started treatment yet. It compares this new medicine to an existing treatment to see if it's as good at reducing the amount of HIV in the body.
For: HIV-1 InfectionUnited States · Argentina · Canada